The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Regulatory News (STX)

Share Price Information for Shield Thera (STX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.90
Bid: 1.80
Ask: 2.00
Change: 0.375 (24.59%)
Spread: 0.20 (11.111%)
Open: 1.525
High: 1.90
Low: 1.90
Prev. Close: 1.525
STX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) - Shield Therapeutics Plc

24 May 2023 12:00

RNS Number : 5192A
Peel Hunt LLP
24 May 2023
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Peel Hunt LLP

(b) Name of offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Shield Therapeutics Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Shield Therapeutics Plc

(d) Date dealing undertaken:

23 May 2023

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

 

N/A

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

Ordinary Shares

Purchase

59,344

6.83 GBx

6.79 GBx

Ordinary Shares

Sale

40,286

6.98 GBx

6.93 GBx

 

 (b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

 

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

Date of disclosure:

24 May 2023

 

Contact name:

Alexandra Forner

Telephone number:

0207 847 4740

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FERGCGDUGUDDGXS
Date   Source Headline
14th Sep 20207:00 amRNSNotice of Results
28th Aug 202012:21 pmRNSTotal Voting Rights Update
6th Aug 20202:21 pmRNSAEGIS-H2H study reanalysis
31st Jul 20207:00 amRNSTotal Voting Rights update
16th Jul 20207:00 amRNSPT20 paper publication
30th Jun 20207:00 amRNSTotal Voting Rights Update
26th Jun 20207:00 amRNSAppointment of Non-Executive Director
18th Jun 20203:18 pmRNSResults of 2020 Annual General Meeting
3rd Jun 20207:00 amRNSFeraccru®/Accrufer® publications
29th May 202011:25 amRNSTotal Voting Rights Update
28th May 20207:00 amRNSInvestor presentations
26th May 20207:00 amRNSAppointment of Chairman
22nd May 20204:15 pmRNS2019 Annual Report and 2020 AGM Notice
21st May 20204:40 pmRNSSecond Price Monitoring Extn
21st May 20204:35 pmRNSPrice Monitoring Extension
21st May 20207:00 amRNSPreliminary Results
19th May 20207:00 amRNSNotice of Results
11th May 20201:15 pmEQSHardman & Co Research: Shield Therapeutics (STX): Reassuring trading update
1st May 20207:00 amRNSBusiness and trading update
30th Apr 20205:23 pmRNSTotal Voting Rights Update
27th Apr 20207:00 amRNSFurther re. Directorate Change
22nd Apr 20207:00 amRNSDirectorate Change
26th Mar 20204:42 pmRNSSecond Price Monitoring Extn
26th Mar 20204:36 pmRNSPrice Monitoring Extension
20th Mar 202011:36 amRNSHolding(s) in Company
17th Mar 20202:06 pmRNSSecond Price Monitoring Extn
17th Mar 20202:00 pmRNSPrice Monitoring Extension
17th Mar 20207:00 amRNSAEGIS-H2H study update
6th Mar 20207:00 amRNSInvestor Presentation
2nd Mar 20204:41 pmRNSBlock Listing Application
21st Feb 202011:14 amRNSHolding(s) in Company
28th Jan 202012:15 pmEQSHardman & Co Research: Shield Therapeutics (STX): Good demand for Feraccru in Europe
27th Jan 20207:00 amRNSBusiness and trading update
24th Jan 20207:00 amRNSInvestor presentations
14th Jan 20207:15 amEQSHardman & Co Research: Shield Therapeutics (STX): Taking on China
8th Jan 20207:00 amRNSChina licence agreement for Feraccru/Accrufer
12th Dec 20195:30 pmRNSEland Oil & Gas
29th Nov 20193:31 pmRNSHolding(s) in Company
25th Nov 20197:00 amRNSQCA Corporate Governance Code
30th Oct 20197:30 amEQSHardman & Co Research: Shield Therapeutics (STX): More choice for clinicians and patients
22nd Oct 20197:00 amRNSPositive results presented at UEG Week 2019
26th Sep 20197:00 amRNSInvestor Presentation
2nd Sep 20199:14 amEQSHardman & Co Research: Shield Therapeutics (STX): FDA approval ushers in a new era for Shield
29th Aug 20197:00 amRNSInvestor presentations
15th Aug 201910:17 amRNSDirector/PDMR Shareholding
7th Aug 20197:00 amRNSHalf-year Report
5th Aug 201911:22 amEQSHardman & Co Research: Shield Therapeutics (STX) FDA approval opens door to major US opportunity
31st Jul 20191:21 pmRNSNotice of Results
26th Jul 20192:05 pmRNSSecond Price Monitoring Extn
26th Jul 20192:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.